GlassScriptPhysician profile
Todd R Adams
NPI 1144433277
$1,104.46
in general payments reported to CMS, 2019-2025
11 companies · $261 in 2025
The $261 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $119 · 2021: $81.26 · 2022: $151 · 2023: $169 · 2024: $129 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $471.61 | 2019-2025 | Optis, Esprit, Diamondback Peripheral |
| Cardiovascular Systems INC. | $157.68 | 2019-2023 | Diamondback Coronary |
| Medtronic, INC. | $130.16 | 2022 | |
| Bard Peripheral Vascular, INC. | $124.70 | 2019-2020 | |
| Abiomed | $73.17 | 2019-2025 | |
| Boston Scientific Corporation | $71.30 | 2024-2025 | Opticross 35, Varithena Administration Pack |
| Shockwave Medical, INC | $29.81 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.91 | 2019 | |
| Werfen USA LLC | $16.23 | 2022 | |
| Pfizer INC. | $12.89 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.